Bristol-Myers Squibb (BMY) has been in the spotlight recently with a range of reports showcasing its performance and future prospects. Viewed as an undervalued stock by several billionaires, the biotech giant has attracted a lot of investor attention. Despite a \">
weak guidance\" and a planned $2 billion in cost cuts by 2027, analysts have remained largely bullish on the company, citing its attractive yield and potential long-term benefits. Furthermore, the company's move to acquire
cell therapy partner 2seventy bio for a sum of $286 million is expected to enhance its position in the market. BMY's stock took a slight dip following a rise in the market, but the company has managed to recover, with its
shares crossing the 4% yield mark. Moreover, the European Commission (EC) has approved Bristol-Myers Squibb’s
Breyanzi for non-Hodgkin lymphoma (NHL) treatment. On a more concerning note, the company's shareholders have faced a 7.2% loss due to a 5.4% drop in stock over the past week. Finally, the company's Q4 sales surpassed expectations, yet full-year sales guidance fell short.
Bristol-Myers Squibb BMY News Analytics from Fri, 06 Sep 2024 07:00:00 GMT to Sat, 22 Mar 2025 20:09:23 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 2
